



## **Nkarta to Participate in Upcoming Investor Conference**

September 3, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

### **H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference**

September 10, 2024

12:30 p.m. ET – fireside chat

A simultaneous webcast of each event will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately 90 days.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

### **Nkarta Media/Investor Contact:**

Greg Mann

Nkarta, Inc.

[gmann@nkartatx.com](mailto:gmann@nkartatx.com)